News

POTOMAC, Maryland – February 09, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announced the expansion of its Phase 2 CALMA trial for IGC-AD1 into Colombia, South America, through the addition of Grupo de Neurociencias de Antioquia (“GNA”).   This expansion marks a pivotal operational milestone as IGC enters a region internationally recognized for its unique, genetically linked Alzheimer’s population.  The GNA site is the latest addition to a

POTOMAC, MARYLAND – February 2, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today reported it has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer’s disease. 

POTOMAC, MARYLAND – January 22, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (“AI”) to develop innovative treatments for Alzheimer’s disease, today announced the addition of Integrative Clinical Trials,

Hybrid Trial Model Enhances Participant Access, Retention, and Enrollment Efficiency Across Underserved and Rural Communities

POTOMAC, MARYLAND – January 6, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage pharmaceutical company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer’s disease,

New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer’s Drug Development

New Patent Expands IGC Pharma’s Pharmaceutical Cannabinoid Portfolio Beyond Alzheimer’s Disease

POTOMAC, MARYLAND – October XX, 2025 – IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer’s disease,

POTOMAC, MARYLAND – December 15, 2025 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for

POTOMAC, MD December 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer’s disease, today